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Abstract
Purpose—High doses of gabapentin were associated with pancreatic acinar cell tumors in male
Wistar rats, but there is little published epidemiological data regarding gabapentin and
carcinogenicity. We explored the association between gabapentin and cancer in a United States
(US) medical care program, and followed up nominally significant associations in a United
Kingdom (UK) primary care database.
Methods—In the US Kaiser Permanente Northern California (KPNC) health system, we
performed nested case-control analyses of gabapentin and 55 cancer sites and all-cancer combined
using conditional logistic regression. Up to ten controls were matched to each case on year of
birth, sex, and year of cohort entry. No other covariates were included in models. Only
dispensings for gabapentin 2 years or more prior to index date were considered. Nominally
significant associations with an odds ratio > 1.00 and p < 0.05 for three or more dispensings versus
no dispensings were followed up by similar nested-case control analyses in the UK General
Practice Research Database (GPRD), adjusting for potential indications for gabapentin and risk
factors for the specific cancers.
Results—The following analyses had OR>1.00 and p<0.05 for three or more dispensings of
gabapentin versus no dispensing (2-year lag) in KPNC, and were also examined in the GPRD: all-
cancer, breast, lung and bronchus, urinary bladder, kidney/renal pelvis, stomach, anus/anal canal/
anorectum, penis, and other nervous system. These cancers were not statistically significantly
associated with gabapentin in the GPRD case-control studies (2-year lag). The GPRD and KPNC
studies did not identify a statistically significant increased risk of pancreatic cancer with >2
prescriptions of gabapentin in 2-year lagged analyses.
Conclusions—The epidemiological data in a US cohort with up to 12 years of follow-up and a
UK cohort with up to 15 years of follow up do not support a carcinogenic effect of gabapentin use.
However, the confidence intervals for some analyses were wide, and an important effect cannot be
confidently excluded.
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INTRODUCTION
Gabapentin was approved in the United States (US) as adjunctive therapy for partial seizures
in December 1993 and for treatment of post-herpetic neuralgia (PHN) in May 2002. In the
United Kingdom (UK), gabapentin was approved as adjunctive therapy for partial seizures
on May 1993, and is also indicated for the treatment of peripheral neuropathic pain such as
painful diabetic neuropathy (PDN) and PHN in adults. Gabapentin has also been prescribed
off-label for other pain conditions,1 and is considered an adjunctive therapy for cancer pain
according to the World Health Organization (WHO) analgesic ladder.2
High doses of gabapentin were associated with pancreatic acinar cell tumors in male Wistar
rats.3 There is one published epidemiological study of gabapentin and cancer. The
association of gabapentin with cancer was evaluated in a case-control screening study of the
association of 105 drugs with 55 cancers in Kaiser Permanente Northern California (KPNC),
1994–2006.4 The only cancer that met the screening criteria for possibly increased cancer
risk with gabapentin exposure was renal (including renal pelvis) cancer. This association
was judged to be likely due to or substantially accentuated by confounding by cigarette
smoking and hypertension. The current paper reports the full results of the KPNC study for
gabapentin and each cancer.
We also conducted a series of epidemiologic studies using the United Kingdom General
Practice Research Database (GPRD) to assess the relationship between gabapentin and (1)
pancreatic cancer, based on the rat findings; (2) renal cancer, based on the published KPNC
findings; (3) and those cancers with OR>1.00 and p<0.05 for three or more dispensings of
gabapentin versus no dispensing of gabapentin in the KPNC study.
METHODS
KPNC Study Population and Methods
The details of the case-control screening study of gabapentin with 55 cancers in Kaiser
Permanente Northern California (KPNC), 1994–2006 were published.4 The study was
approved by the Kaiser Permanente Institutional Review Board. In brief, KPNC is an
integrated health care plan (including comprehensive inpatient and outpatient care and
pharmacy services), serving over 3 million current members, comprising about 30% of the
residents in the San Francisco Bay area and the Central Valley of California. The
membership is fairly representative of the local population except for some under-
representation of both extremes of the economic spectrum.
The study design was a nested case-control study within a cohort of 6.6 million KPNC
subscribers with drug coverage August 1994-December 31, 2006. Cohort entry began
August 1994, or at the time of joining the program and having drug coverage if later than
August 1994. Follow-up was through the earlier of (1) December 31, 2006, (2) diagnosis of
the cancer of interest, or (3) leaving KPNC for any reason, including death.
Cancer categories were based on invasive cancers at each cancer site (plus non-invasive
urinary bladder cancers) listed in the International Classification of Diseases for Oncology,
Version 3 (ICD-O-3) except for non-melanoma skin cancers.5 Cancer cases were risk set
matched with up to 10 controls by year of birth, sex, and year of cohort entry. The index
date was the date of incident cancer for cases. The index date for controls was chosen so as
to give the controls equal follow-back time to that of the case for ascertainment of prior use
of gabapentin. Conditional logistic regression calculated the odds ratio (OR) as the estimate
of the relative risk of cancer associated with 1, 2, and ≥3 prescription dispensings versus no
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use of gabapentin at least 2-years before the index date. The 2-year lag was defined a priori
to control for prediagnostic prescribing for symptoms possibly related to cancer.4, 6 These
analyses were not adjusted for covariates other than the matching variables.
GPRD Study Population and Methods
Study Design—Nominally significant associations with OR>1.00 and p<0.05 for three or
more dispensings versus no dispensings in KPNC were followed up by similar nested-case
control analyses in the GPRD, adjusting for potential indications for gabapentin and the
main risk factors for the specific cancers. Pancreatic cancer, though not significant in
KPNC, was also evaluated in the GPRD.
GPRD study protocols were approved by the Independent Scientific Advisory Committee
(ISAC) of the GPRD and posted to ClinicalTrials.gov prior to analysis (ClinicalTrials.gov
Identifiers NCT01138124 and NCT01236053). The results reported herein are from the
protocol-specified analyses. The pancreatic and renal studies were conducted initially
(NCT01138124), and the additional cancers were subsequently assessed with modifications
in the analysis (NCT01236053). The main modification was exclusion of cases and controls
with a prior history of cancer before the index date in the analyses of the additional cancers,
to limit misclassification of primary cancer diagnosis codes that may be recurrent or
metastatic. In the analysis of the additional cancers, back pain was added as a covariate to
further control for potential confounding by indication. However, supplemental analyses of
gabapentin and the risk of pancreatic and renal cancers were also performed under these
modifications (i.e. excluding those with prior history of other cancer before index date and
further adjusting for back pain) to allow for comparability of study results.
Data Source—The GPRD, managed by the UK Medicines and Healthcare products
Regulatory Agency (MHRA), comprises the entire computerized medical records of a
sample of general practitioners (GPs) in England and Wales. All members of the population
are registered with a single practice, which centralizes the medical information from GPs,
specialist referrals, and hospital attendances. This study is based on data from about a 6%
representative sample of the UK population. Data recorded in the GPRD includes
demographic information, prescription details, clinical events, preventive care provided,
specialist referrals, hospital admissions and their major outcomes. Data are retrieved by
means of the Oxford Medical Information Systems (OXMIS) and READ codes.7
Study Cohort—Nested case-control analyses were conducted in a cohort of subjects in the
GPRD 1993–2008. Entry into the study cohort began Jan 1, 1993 for all those who were
registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
The ascertainment period for gabapentin use was from Jan 1, 1993 through Dec 31, 2008.
The ascertainment period for incident cancers was from Jan 1, 1995 through Dec 31, 2008.
Follow-up ended earlier if the respective cancer was diagnosed, or if the subject left the
GPRD for any reason including death, whichever came first.
Case Definition—The cancer outcomes were defined by READ/OXMIS codes
(Supplemental Table 1). The code list for all-cancer was derived from clinical review of all
cancer, neoplasm, and oncology related READ/OXMIS codes by William T. Hamilton, MD,
FRCP, FRCGP, chair of the early diagnosis subgroup within the UK National Cancer
Research Institute, Primary Care Section. All-cancer included metastatic disease, carcinoma
in situ, and non-melanotic skin cancers. The codes for specific cancers were reviewed by a
physician (MCI). The specific cancers included carcinoma in situ, and excluded metastatic
disease to those sites. The index date for the case was the earliest date of diagnosis of the
respective cancer in the GPRD.
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Control Selection—Patients with a first diagnosis of the respective cancer 1995–2008
were risk set matched with up to 10 controls within the same General Practice for age at
cohort entry (within two years), sex, and year of entry into the study cohort (within one
year). The index date for controls was set as the date at which the follow-up time from
cohort entry was the same as the case. The index date was chosen so as to give the control
equal follow-up time to that of the case for ascertainment of use of gabapentin. Cases and
controls were required to have at least 2 years of follow-up in the study cohort before their
index date. For pancreatic and renal cancer, cases and controls could have a prior diagnosis
of another cancer. For the analyses of the other cancers (and supplemental analyses of
pancreatic and renal cancer), cases were required to be free of other cancers prior to the
index date for the specific cancer, and controls were required to be free of any cancer prior
to the index date.
Gabapentin exposure—The exposure of interest was gabapentin use as defined by
prescriptions recorded by the general practitioner (British National Formulary Codes). Data
on gabapentin prescriptions were obtained for cases and controls from cohort entry to the
index date. Exposure to gabapentin was assessed as ever/never, number of prescriptions,
cumulative duration, and cumulative dose, from cohort entry to 2-years prior to the index
date (2-year lagged exposure). The 2-year lagged exposure attempted to account for
protopathic bias (gabapentin prescribing for cancer-related pain or worsening of neuropathic
or non-neuropathic pain prior to clinical cancer diagnosis) and latency in carcinogenesis
(non-etiological exposure to gabapentin in the period between cancer onset and cancer
diagnosis). Tertiles of each exposure measure (prescription, cumulative duration, cumulative
dose) for the pancreatic and renal analyses were based on the pooled pancreatic and renal
controls; tertiles for the additional cancers were based on the all-cancer controls. Explicit
indications for each gabapentin prescription were not recorded in the GPRD.
Covariates—The relevant potential confounders were the consistent risk factors for each
cancer (defined a priori) as well as the major indications for gabapentin use in the UK
(epilepsy, diabetes, neuropathic pain, back pain). Covariates were assessed up to the index
date, unless otherwise specified. The following were controlled by either matching or
covariate adjustment in all analyses: Age at cohort entry; sex; calendar year of cohort entry;
body mass index (BMI); smoking, diabetes, epilepsy, and neuropathic pain. Covariates for
pancreatic cancer included diabetes ≥2 years prior to index date and chronic pancreatitis ≥2
years prior to index date (the lag was incorporated since these can be also be early
symptoms of neoplastic destruction of pancreatic tissue).8–10 Covariates for renal cancer
included history of hypertension and diuretic use.11 Additional covariates for the other
cancers were history of back pain and (1) all-cancer: alcohol consumption; (2) breast:
previous hysterectomy, current (within 6 months of index date) or previous hormone
replacement therapy; benign breast disease; alcohol consumption;12 (2) lung and bronchus:
chronic obstructive pulmonary disease (COPD); alcohol consumption; (3) urinary and
bladder – no additional covariates;13 (4) stomach: upper gastrointestinal disorders, acid-
suppressing drugs up to 6 months before index date, alcohol consumption;14 (5) anus, anal
canal, and anorectum: human immunodeficiency virus (HIV) and human papilloma virus
(HPV, anogenital warts, condylomas); (6) penis: HIV; HPV (anogenital warts, condylomas);
phimosis/balanitis; (7) other nervous system (defined as malignant meningioma, spinal
glioblastoma, and malignant tumors of cranial and peripheral nerves) – no additional
covariates.
Analytic methods—Conditional logistic regression models for matched case and control
data estimated the crude and multivariable adjusted relative risk (estimated by the odds ratio
[OR]) for the respective cancer in relation to gabapentin exposure, conditional on the
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matching factors. Separate analyses were performed for all-cancer and each individual
cancer. Four exposure comparisons (ever versus never, number of prescriptions, duration of
exposure, and cumulative exposure) were evaluated, with a 2 year lag from the index date.
For the more common cancers (all-cancer, lung, and breast), longer exposures were also
assessed (>1 y, >2 y, >3 y cumulative duration versus no exposure). The primary analyses
were the multivariable adjusted 2-year lagged models. Adjustments were not made for
multiple comparisons. Exploratory models with unlagged exposure (gabapentin usage up to
the index date) were performed to gain insight into the extent of protopathic bias (reduction
in effect estimates with 2-year lagged exposure compared to unlagged exposure) or sample
size effects (widening of confidence intervals with lagged exposure compared to unlagged
exposure).
For the comparison of highest tertile of exposure to no exposure in the 2-year lagged
analysis, the studies were estimated to have an 80% power (2-sided α=0.05) to detect ORs of
1.20 or greater for all-cancer; 1.62 for lung; 1.78 for breast; 2.34 for bladder; 2.60 for
kidney, pancreas and stomach; 7.45 for anus; 10.49 for penis; and 23.45 for other CNS. This
assumed a 0.6% overall gabepentin exposure rate and UK Office of National Statistics
cancer incidence rates.
RESULTS
Kaiser Permanente Northern California
There were 109,879 exposures to gabapentin in the cohort of 6,608,681 subscribers to
KPNC.4 Table 1 reports the ORs of all-cancer and the 55 individual cancers for 1-;, 2-, and
≥3 dispensings of gabapentin versus no dispensing in the 2-year lagged analysis. The
following analyses, with adjustment for matching variables only, had OR>1.00 and p<0.05
for three or more dispensings of gabapentin versus no dispensing, and were followed up in
the GPRD: 1) all-cancer, OR 1.10 (95% CI 1.02–1.18); 2) breast, OR 1.19 (1.01–1.39); 3)
lung and bronchus, OR 1.34 (1.13–1.60); 4) urinary bladder, OR1.41 (1.07–1.87); 5) kidney/
renal pelvis, OR 1.71 (1.18–2.47); 6) stomach, OR 1.64 (1.01–2.64); 7) anus, anal canal, and
anorectum, OR 2.70 (1.17–6.25); 8) penis, OR 6.68 (1.47–30.28); 9) and other nervous
system, OR 6.67 (1.11–39.90).
General Practice Research Database
Pancreatic Cancer—3,149 pancreatic cancer cases were risk set matched to 30,026
controls, with mean duration of follow up from cohort entry of 9.0–9.1 years (Table 2).
1.8% (n=56) of pancreatic cancer cases were exposed to gabapentin, relative to 0.8%
(n=253) of the controls. The distribution of time from first gabapentin prescription to index
date for the gabapentin-exposed pancreatic cancer cases and controls demonstrates that the
first gabapentin prescription in the cancer cases was skewed toward exposure within the 100
days prior to the specific diagnosis code for cancer (Figure 1). In the 2-year lagged exposure
window, 0.8% (n=24) of pancreatic cancer cases were exposed to gabapentin, relative to
0.5% (n=143) of the controls (Supplemental Table 2). The OR of pancreatic cancer with
gabapentin exposure was sensitive to modeling assumptions (Table 3). Although ever
exposure was associated with a significantly increased risk of pancreatic cancer in the
unlagged analysis (multivariable adjusted OR 1.82 [95% CI 1.34, 2.46]), the OR was
attenuated and not significant in the 2-year lagged exposure analysis (adjusted OR 1.33
[95% CI 0.85, 2.08])(Supplemental Table 3). There was no evidence of a positive dose-
response relationship with increasing number of prescriptions, duration of exposure, or
cumulative dose; point estimates were consistently lower for the highest exposure tertiles
(adjusted ORs 0.87–1.17 relative to no exposure) than the lowest exposure tertiles (adjusted
ORs 1.95–2.88), even in the 2-year lagged analysis.
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Renal Cancer—1,981 renal cancer cases were risk set matched to 19,046 controls, with
mean duration of follow up from cohort entry of 9.4–9.5 years (Table 4). 1.6% (n=32) of
renal cancer cases were exposed to gabapentin, relative to 0.9% (n=166) of the controls.
Similar to the gabapentin-exposed pancreatic cancer cases, the distribution of gabapentin
exposure was skewed toward exposure within the 100 days prior to the specific diagnosis
code for renal cancer (Figure 1). In the 2-year lagged exposure window, 0.7% (n=13) of
renal cancer cases were exposed to gabapentin, relative to 0.4% (n=76) of the controls
(Supplemental Table 4). The OR of renal cancer with gabapentin exposure was sensitive to
modeling assumptions, particularly given the low numbers of gabapentin exposed cases and
controls in the tertile analyses (Table 5). Ever exposure was associated with a significantly
increased risk of renal cancer in the unlagged analysis (adjusted OR 1.68 [95% CI 1.13,
2.49]); the point estimate was similar in the 2-year lagged analysis (adjusted OR 1.63 [0.89,
2.97])(Supplemental Table 5). Dose-response estimates were limited by the low numbers of
exposed cases, especially in the 2-year lagged exposure analyses.
Other Cancers—The additional cancers in the KPNC study nominally (p<0.05) associated
with gabapentin were not statistically significantly associated with gabapentin in the GPRD
case-control studies. The results based on ever/never exposure and tertiles of duration of
exposure (2-year lag) are shown in Table 6; the results were similar for tertiles of number of
prescriptions and of cumulative dose (supplementary results available at GSK Clinical Study
Register15 and Supplemental Tables 6–15). There was a trend (p=0.054) for association of
the highest tertile of gabapentin cumulative duration (>5.56 months 2-year lagged exposure)
with breast cancer (OR 1.49, 95% CI 0.99–2.04). Longer cumulative durations of gabapentin
exposure were assessed (>1 y, >2 y, or >3 y) for the more common cancers—all cancer,
lung, and breast; long durations of gabapentin exposure were not significantly associated
with increased risk of these cancers. The results for breast cancer were OR 1.48 (95% CI
0.92, 2.39) for >1y duration, OR 1.62 (95% CI 0.79, 3.29) for >2y duration, and OR 0.76
(95% CI 0.18, 3.21) for >3y duration.
Supplemental analyses of pancreatic and renal cancer were reported for comparability
(Table 6). The numbers of incident pancreatic and renal cancer cases were reduced by
approximately 1/3 after excluding those with prior history of other cancers or non-specific
cancer codes before their index date. Ever exposure to gabapentin (2-year lag) was
marginally associated with an increased risk of pancreatic cancer (adjusted OR 1.68 [95%
CI 1.00, 2.82] relative to no exposure). The highest tertiles of gabapentin exposure were not
significantly associated with risk of pancreatic cancer (point estimates of OR 1.00–1.36
relative to no exposure). Ever exposure to gabapentin and the highest tertiles of exposure
were not significantly associated with renal cancer.
DISCUSSION
Gabapentin was approved in the US and UK in 1993. Despite being prescribed for epilepsy
and pain, the exposure rate in the general population is low (<1%).4 Therefore, large
population-based studies are required to accrue sufficient exposure and outcomes for safety
studies, especially for rare outcomes such as pancreatic cancer. The GPRD and KPNC
cohorts are well suited to study gabapentin and carcinogenicity. These data sources include
large numbers of drug recipients with complete cancer follow-up, often long-term, in a
comprehensive health care system. They contain objective data on the prescribing or
dispensing of prescriptions, without recall bias.
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Pancreatic and Renal Cancer
The relationship between gabapentin and pancreatic and renal cancer was sensitive to
modeling assumptions. Increased risks of cancer were observed with lower exposures, or
shorter duration of exposures, and closer to the index diagnosis of cancer. Relative risks
were attenuated toward unity with the lag analysis, and there was no evidence of a dose
response relationship with increasing numbers of prescriptions, cumulative dose, or duration
of use. The pattern of increasing OR for cancer with very short gabapentin exposures (<2
months), lack of a positive dose response, and decreasing OR with longer exposures is not a
pattern consistent with a mutagenic or non-mutagenic carcinogen.16 The decreasing ORs
with lagged analysis and with increasing exposure suggests that protopathic bias is inflating
the OR.17, 18 Protopathic bias (reverse causation) occurs when a pharmaceutical agent is
prescribed for an early manifestation of a disease that has not yet been diagnostically
detected or formally recorded in the medical record.19, 20 Elements of protopathic bias were
observed in studies of proton pump inhibitors and H2-antagonists with risk of gastric cancer,
and of acetaminophen with cancer mortality.17, 18, 21 In these examples, elevations in cancer
risk diminished with duration of follow-up, returning to baseline with long-term use of the
drug.
A plausible explanation is that individuals are prescribed gabapentin for cancer-related pain
or worsening of other non-neuropathic or neuropathic pain in the context of pancreatic
cancer, prior to the specific cancer diagnosis being recorded in the GPRD. Gabapentin is
considered an adjunctive treatment for cancer pain in the World Health Organization
(WHO) analgesic ladder.2 Indeed, the first gabapentin prescription in the cancer cases was
skewed toward exposure within the 100 days prior to the specific diagnosis code for cancer
(Figure 1). Excluding exposure in the time period before the index date (lagged exposure)
can control for protopathic bias, but misspecification of the lag period may result in spurious
association from residual protopathic bias, or reduce power for detecting associations. A 2-
year lagged exposure was incorporated in all analyses a priori based on recommendations
for addressing protopathic bias for drugs that may be used to treat early symptoms of cancer,
and for comparability of the results across cancers in GPRD and KPNC;6 however, the
optimal specification of the lag period is likely to vary across cancer types based on different
symptoms, pain characteristics, time courses, and treatment patterns.18 For instance,
retroperitoneal cancers such as pancreatic or renal may be more likely to present as back
pain that would serve as the protopathic stimulus for gabapentin treatment.22
Taken together, the GPRD and KPNC studies did not identify a statistically significant
increased risk of pancreatic cancer with >2 prescriptions of gabapentin in 2-year lagged
analyses.
Other cancers
The additional cancers in the KPNC study nominally associated with gabapentin (p<0.05)
were not statistically significantly associated with gabapentin in the 2-year lag analysis of
the GPRD case-control studies. There was a suggestion of association between gabapentin
and breast cancer based on the OR point estimates. In the KPNC, the OR of breast cancer for
≥3 dispensings versus no dispensing of gabapentin was 1.19 (1.01–1.39), p=0.03. In the
GPRD, the adjusted OR of breast cancer for 3–10 prescriptions versus no prescriptions was
OR 1.17 (0.76, 1.81), p = 0.47; for >10 prescriptions the OR was 1.36 (0.95, 1.96) p = 0.09.
Given the low overall gabapentin exposure frequency, statistical power was limited for the
evaluation of the effect of long durations or very high cumulative exposures, especially for
the less common cancers such as anal cancer, penile cancer, and other nervous system
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cancers. Nonetheless, ever exposure to gabapentin was not statistically significantly
associated with these less common cancers.
Strengths and limitations
The study should be interpreted in the context of its strengths and limitations. Many
strengths of the study are methodological, including the nesting of the case-control study
within a population-based cohort of patients in KPNC and the GPRD. In KPNC, occurrence
of cancer was ascertained through KPNC's Cancer Registry, which covers all subscribers
and contributes to the local Surveillance, Epidemiology, and End Results (SEER) program.
The accuracy of clinical data and cancer diagnoses was good in previous validation studies
in the GPRD.23–25 However, the index date of cancer based on the record of a specific
diagnostic code by the general practitioner generally occurs after cancer symptoms, and may
also be recorded after diagnosis by a specialist. This raises the possibility of protopathic bias
—gabapentin prescription for cancer-related pain prior to the formal diagnosis in the
GPRD.2
Imprecision in the measurement of potential confounders and unmeasured confounders (e.g.
alcohol use) may result in residual confounding; this includes missing data in BMI and
smoking, and the parameterization of smoking status, hypertension, and diuretic usage.
Given the low overall gabapentin exposure frequency, statistical power was limited for the
evaluation of the effect of long durations or very high cumulative exposures. Follow-up may
not be long enough to detect a carcinogenic effect with a latency of more than a few years.
Misclassification of exposure was possible for analyses of cumulative duration or
cumulative dosage given missing data on daily dose or quantity dispensed; misclassification
was likely to be non-differential with respect to cases and controls, and could weaken our
ability to detect associations.
Conclusion
Studies in two large healthcare systems—KPNC in the US with up to 12 years of follow-up
and GPRD in the UK with up to 15 years of follow-up—do not support a statistically
significant association of >2 prescriptions of gabapentin and pancreatic cancer in the 2-year
lag analyses. Furthermore, the nominal gabapentin associations with other cancers in the
KPNC study were not statistically significant in the GPRD study in the 2-year lag analyses.
However, the confidence intervals for some analyses were wide, and an important effect
cannot be confidently excluded.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
• Studies in two large healthcare systems—Kaiser Permanente Northern
California (KPNC) in the United States and the General Practice Research
Database (GPRD) in the United Kingdom—do not support a statistically
significant association between gabapentin exposure (>2 prescriptions with a 2-
year lag) and pancreatic cancer.
• Nominal gabapentin associations with other cancers in KPNC were not
statistically significant in the GPRD.
• Evidence of protopathic bias (gabapentin prescribing for cancer-related pain
prior to the formal diagnostic record of cancer) was observed for pancreatic and
renal cancer in the GPRD.
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Figure 1.
Distribution of time from first gabapentin prescription (in days) to index date in gabapentin-
exposed pancreatic cancer (A) and renal cancer (B) cases and controls in the GPRD
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Table 1
Risk of cancer with 1-, 2-, and ≥3 dispensings of gabapentin versus no dispensing in KPNC
Cancer Site (alphabetical after
“Any Cancer”)
GP
exposed
cases
(N)
OR (95%CI) and p-value for 1-, 2-, and ≥3 dispensings of gabapentin versus no
dispensings (2-year lag)
1 dispensing vs none 2 dispensings vs none ≥3 dispensings vs none
Any Cancer 1678 1.05 (0.96–1.14) p=0.276 1.20 (1.06–1.36) p=0.005 1.10 (1.02–1.18) p=0.009**
Anus/anal canal/Anorectum 9 0.41 (0.06–3.03) p=0.382 1.42 (0.17–11.52) p=0.744 2.70 (1.17–6.25) p=0.021*
Biliary 7 Inestimable 3.35 (1.06–10.57) p=0.040 0.81 (0.25–2.63) p=0.726
Bones/joints 4 4.30 (1.11–16.62) p=0.035 Inestimable 1.29 (0.16–10.30) p=0.812
Brain 21 1.84 (0.93–3.65) p=0.079 0.87 (0.20–3.73) p=0.851 1.16 (0.58–2.32) p=0.673
Breast 352 1.09 (0.90–1.31) p=0.375 1.35 (1.03–1.78) p=0.032 1.19 (1.01–1.39) p=0.038*
Cervix uteri 6 0.60 (0.14–2.50) p=0.481 1.41 (0.32–6.22) p=0.647 0.49 (0.12–2.01) p=0.320
Colon excl. Rectum 145 1.13 (0.85–1.50) p=0.391 1.13 (0.73–1.74) p=0.586 0.96 (0.75–1.24) p=0.768
Comb mouth-pharynx1 9 0.91 (0.28–2.96) p=0.874 Inestimable 1.14 (0.49–2.68) p=0.760
Corpus uteri 36 0.39 (0.20–0.76) p=0.006 0.60 (0.28–1.29) p=0.189 0.64 (0.40–1.00) p=0.052
Esophagus 17 0.82 (0.30–2.28) p=0.707 2.67 (0.89–8.05) p=0.081 1.24 (0.62–2.48) p=0.550
Eye and orbit 0 Inestimable Inestimable Inestimable
Gallbladder 3 1.84 (0.40–8.46) p=0.433 Inestimable 0.55 (0.07–4.17) p=0.563
Heart/soft tissue 12 1.19 (0.42–3.38) p=0.748 2.31 (0.66–8.12) p=0.190 0.99 (0.39–2.48) p=0.978
Hodgkin lymphoma 10 1.93 (0.66–5.63) p=0.228 2.95 (0.61–14.19) p=0.178 1.96 (0.67–5.75) p=0.222
Kidney/renal pelvis 70 1.20 (0.75–1.94) p=0.450 2.48 (1.46–4.24) p=0.001 1.71 (1.18–2.47) p=0.004*
Larynx 10 1.35 (0.53–3.46) p=0.531 2.71 (0.76–9.72) p=0.126 0.49 (0.12–2.05) p=0.331
Lip 8 1.11 (0.39–3.15) p=0.841 0.67 (0.09–5.08) p=0.695 1.11 (0.34–3.69) p=0.861
Liver/intrahep.bile duct 36 2.19 (1.29–3.72) p=0.004 0.69 (0.17–2.90) p=0.614 1.65 (0.98–2.77) p=0.058
Lung and bronchus 269 0.87 (0.68–1.11) p=0.250 1.50 (1.11–2.02) p=0.008 1.34 (1.13–1.60) p=0.001**
Lymphocytic leukemia 19 1.48 (0.67–3.29) p=0.337 1.68 (0.58–4.85) p=0.335 1.14 (0.55–2.39) p=0.727
Melanoma 73 0.97 (0.63–1.51) p=0.896 1.15 (0.62–2.14) p=0.665 1.11 (0.80–1.54) p=0.534
Monocytic leukemia 0 Inestimable Inestimable Inestimable
Multiple myeloma 27 1.46 (0.81–2.63) p=0.211 0.32 (0.04–2.30) p=0.255 1.11 (0.62–1.97) p=0.730
Myeloid leukemia 16 0.48 (0.15–1.53) p=0.216 0.54 (0.13–2.26) p=0.399 1.64 (0.86–3.12) p=0.134
Nasopharynx 0 Inestimable Inestimable Inestimable
Non-hodgkin lymphoma 87 1.17 (0.82–1.69) p=0.391 1.06 (0.57–1.98) p=0.848 1.16 (0.85–1.60) p=0.356
Nose/nasal cavity/middle ear 2 1.01 (0.13–7.88) p=0.994 Inestimable 1.43 (0.18–11.62) p=0.739
Other digestive organs 6 2.86 (0.59–13.75) p=0.190 6.67 (1.11–39.90) p=0.038 4.33 (0.78–24.07) p=0.094
Other endocrine 1 Inestimable Inestimable 2.50 (0.28–22.37) p=0.413
Other female genital 1 Inestimable Inestimable 1.24 (0.15–9.88) p=0.842
Other leukemia 3 Inestimable Inestimable 1.86 (0.54–6.44) p=0.33
Other male genital 1 3.33 (0.35–32.05) p=0.297 Inestimable Inestimable
Other nervous system 2 Inestimable Inestimable 6.67 (1.11–39.90) p=0.038*
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Cancer Site (alphabetical after
“Any Cancer”)
GP
exposed
cases
(N)
OR (95%CI) and p-value for 1-, 2-, and ≥3 dispensings of gabapentin versus no
dispensings (2-year lag)
1 dispensing vs none 2 dispensings vs none ≥3 dispensings vs none
Other skin 11 2.29 (0.92–5.66) p=0.074 Inestimable 1.49 (0.57–3.85) p=0.416
Other urinary 1 Inestimable Inestimable Inestimable
Ovary 23 0.94 (0.49–1.80) p=0.849 0.62 (0.19–2.00) p=0.426 0.77 (0.40–1.46) p=0.417
Pancreas 46 0.74 (0.41–1.34) p=0.318 0.24 (0.06–0.96) p=0.043 1.23 (0.85–1.78) p=0.282
Penis 3 Inestimable Inestimable 6.68 (1.47–30.28) p=0.014*
Peritoneum/Omentum/Mesentery 7 2.86 (0.76–10.7) p=0.119 Inestimable 1.68 (0.58–4.91) p=0.341
Pleura 1 Inestimable Inestimable Inestimable
Prostate 246 1.10 (0.89–1.36) p=0.379 1.03 (0.74–1.43) p=0.855 0.78 (0.64–0.94) p=0.011†
Rectum/Rectosigmoid 30 0.70 (0.39–1.26) p=0.236 1.03 (0.52–2.06) p=0.925 0.41 (0.21–0.80) p=0.009††
Retroperito-neum 1 1.64 (0.19–14.30) p=0.652 Inestimable Inestimable
Salivary glands 8 2.55 (0.72–9.06) p=0.147 Inestimable 1.67 (0.64–4.36) p=0.298
Small intestine 8 0.82 (0.19–3.48) p=0.789 3.00 (0.82–10.88) p=0.096 2.05 (0.58–7.33) p=0.268
Stomach 27 0.65 (0.30–1.41) p=0.276 Inestimable 1.64 (1.01–2.64) p=0.045*
Testis 3 Inestimable Inestimable 1.82 (0.40–8.20) p=0.437
Thyroid 26 1.06 (0.46–2.48) p=0.886 2.16 (0.90–5.22) p=0.087 1.51 (0.86–2.66) p=0.155
Trachea 0 Inestimable Inestimable Inestimable
Unspecified 75 1.65 (1.12–2.42) p=0.011 1.55 (0.86–2.78) p=0.143 1.20 (0.82–1.74) p=0.349
Ureter 4 2.02 (0.44–9.22) p=0.366 3.40 (0.35–32.69) p=0.290 0.74 (0.10–5.68) p=0.771
Urinary bladder 100 1.20 (0.84–1.71) p=0.309 0.70 (0.34–1.43) p=0.325 1.41 (1.07–1.87) p=0.015*
Uterus 2 4.83 (0.44–53.25) p=0.199 5.00 (0.45–55.14) p=0.189 Inestimable
Vagina 3 1.70 (0.20–14.12) p=0.624 Inestimable 2.49 (0.53–11.73) p=0.249
Vulva 3 0.54 (0.07–4.14) p=0.554 Inestimable 1.11 (0.25–4.84) p=0.895
KPNC, Kaiser Permanente Northern California; GP, gabapentin; OR, odds ratio; CI, confidence interval; vs, versus; excl, excluding; intrahep,
intrahepatic; comb, combined.
Inestimable – no gabapentin-exposed cancer cases or no gabapentin-exposed non-cases at the exposure level, p > 0.97.
1
Excludes lip, salivary glands and nasopharynx
*
p<.05, OR>1 for ≥3 dispensings vs no dispensings
**
p<.01, OR>1 for ≥3 dispensings vs no dispensings
†
p<.05, OR<1 for ≥3 dispensings vs no dispensings
††
p<.01, OR<1 for ≥3 dispensings vs no dispensings
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Table 3
Risk of pancreatic cancer with gabapentin exposure in the GPRD
Exposure Model
Without 2 year lag With 2 year lag
Unadjusted OR (95%
CI)
Adjusted OR (95%
CI)1
Unadjusted OR (95%
CI)
Adjusted OR (95%
CI)1
Gabapentin (Ever vs Never) 2.04 (1.51, 2.75) 1.82 (1.34, 2.46) 1.52 (0.98, 2.36) 1.33 (0.85, 2.08)
Gabapentin Prescriptions 2,3
 Tertile1 vs Never 2.82 (1.86, 4.28) 2.53 (1.66, 3.85) 2.75 (1.51, 5.03) 2.44 (1.32, 4.49)
 Tertile2 vs Never 1.80 (0.97, 3.36) 1.65 (0.87, 3.11) 0.55 (0.17, 1.78) 0.48 (0.15, 1.57)
 Tertile3 vs Never 1.35 (0.76, 2.42) 1.17 (0.65, 2.11) 1.31 (0.58, 2.97) 1.11 (0.48, 2.57)
Duration of exposure (mo) 4,5
 Tertile1 vs Never 3.15 (2.04, 4.86) 2.88 (1.85, 4.46) 2.75 (1.47, 5.13) 2.45 (1.31, 4.62)
 Tertile2 vs Never 1.68 (0.94, 2.99) 1.50 (0.83, 2.69) 0.82 (0.29, 2.28) 0.72 (0.26, 2.01)
 Tertile3 vs Never 1.34 (0.75, 2.39) 1.15 (0.64, 2.07) 1.11 (0.49, 2.51) 0.94 (0.41, 2.15)
Cumulative Exposure (g) 6,77
 Tertile1 vs Never 2.90 (1.88, 4.47) 2.65 (1.71, 4.11) 2.19 (1.12, 4.25) 1.95 (0.99, 3.81)
 Tertile2 vs Never 1.87 (1.05, 3.32) 1.64 (0.92, 2.95) 1.42 (0.64, 3.16) 1.21 (0.54, 2.72)
 Tertile3 vs Never 1.34 (0.75, 2.39) 1.15 (0.64, 2.08) 1.01 (0.42, 2.41) 0.87 (0.36, 2.12)
OR, odds ratio; CI, confidence interval; vs, versus; mo, months; g, grams; GPRD, General Practice Research Database.
1
Adjusted for smoking, body mass index, diabetes, chronic pancreatitis, neuropathic pain, epilepsy
2
The tertiles for number of prescriptions in the analysis without 2 year lag are: Tertile 1 (1–2). Tertile 2 (3–8). Tertile3 (9–218).
3
The tertiles for number of prescriptions in the analysis with 2 year lag are: Tertile 1 (1–2). Tertile 2 (3–10). Tertile 3(11–191).
4
The tertiles for cumulative duration in the analysis without 2 year lag are: Tertile 1 (0.01 – 1.55 mo). Tertile 2 (1.56 – 6.44 mo). Tertile 3 (6.45 –
78.36 mo).
5
The tertiles for cumulative duration in the analysis with 2 year lag are: Tertile 1 (0.01 – 1.78 mo). Tertile 2 (1.79 – 7.20 mo). Tertile 3 (7.21 –
64.13 mo)
6
The tertiles for cumulative dose in the analysis without 2 year laq are: Tertile 1 (0.01 – 33.6 g). Tertile 2 (33.7 – 185.0 g). Tertile 3 (185.1 –
7500.2 g).
7
The tertiles for cumulative dose in the analysis with 2 year lag are: Tertile 1 (0.01 – 39.0 g) Tertile 2 (39.1 – 210.0 g). Tertile 3 (210.1 – 5623.8 g).
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Table 5
Relative risk of renal cancer with gabapentin exposure in the GPRD
Exposure Model
Without 2 year lag With 2 year lag
Unadjusted OR (95%
CI)
Adjusted OR (95%
CI)1
Unadjusted OR (95%
CI) p-value
Adjusted OR (95%
CI)1
Gabapentin (Evervs Never) 1.79 (1.22, 2.63) 1.68 (1.13, 2.49) 1.65 (0.91, 2.99) 1.63 (0.89, 2.97)
Gabapentin Prescriptions2,3
 Tertile1 vs Never 2.53 (1.44, 4.44) 2.34 (1.32, 4.14) 2.18 (0.90, 5.32) 2.14 (0.87, 5.28)
 Tertile2 vs Never 1.89 (0.98, 3.63) 1.77 (0.92, 3.43) 1.40 (0.49, 4.01) 1.39 (0.48, 4.02)
 Tertile3 vs Never 0.87 (0.35, 2.19) 0.83 (0.33, 2.11) 1.32 (0.39, 4.47) 1.30 (0.38, 4.47)
Duration of exposure (mo)4,5
 Tertile1 vs Never 3.24 (1.79, 5.85) 2.90 (1.59, 5.28) 2.54 (1.03, 6.25) 2.40 (0.96, 5.98)
 Tertile2 vs Never 1.35 (0.69, 2.65) 1.33 (0.68, 2.63) 0.95 (0.29, 3.12) 0.99 (0.30, 3.29)
 Tertile3 vs Never 1.19 (0.54, 2.63) 1.10 (0.50, 2.45) 1.70 (0.58, 4.96) 1.63 (0.55, 4.84)
Cumulative Exposure (g)
 Tertile1 vs Never 1.89 (0.92, 3.88) 1.75 (0.85, 3.63) 2.03 (0.78, 5.34) 2.05 (0.77, 5.46)
 Tertile2 vs Never 2.44 (1.42, 4.22) 2.34 (1.35, 4.07) 1.78 (0.68, 4.69) 1.70 (0.64, 4.53)
 Tertile3 vs Never 0.99 (0.42, 2.29) 0.91 (0.39, 2.13) 1.15 (0.35, 3.82) 1.15 (0.34, 3.86)
OR, odds ratio; CI, confidence interval; vs, versus; mo, months; g, grams; GPRD, General Practice Research Database.
1
Adjusted for smoking, body mass index, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.
2
The tertiles for number of prescriptions in the analysis without 2 vearlaq are: Tertile 1 (1–2). Tertile 2 (3–8). Tertile 3. (9–218).
3
The tertiles for number of prescriptions in the analysis with 2 yearlag are: Tertile 1 (1–2). Tertile 2 (3–10). Tertile 3 (11–191).
4
The tertiles for cumulative duration in the analysis without 2 yearlag are: Tertile 1 (0.01 – 1.55 mo). Tertile 2 (1.56 – 6.44 mo). Tertile 3 (6.45 –
78.36 mo).
5
The tertiles for cumulative duration in the analysis with 2 year lag are: Tertile 1 (0.01 – 1.78 mo). Tertile 2 (1.79 – 7.20 mo). Tertile 3 (7.21 –
64.13 mo).
6
The tertiles for cumulative dose in the analysis without 2 yearlag are: Tertile 1 (0.01 – 33.6g). Tertile 2 (33.7 – 185.0 g). Tertile 3 (185.1 – 7500.2
g).
7
The tertiles for cumulative dose in the analysis with 2 year lag are: Tertile 1 (0.01 – 39.0g) Tertile 2 (39.1 – 210.0 g). Tertile 3 (210.1 – 5623.8 g).
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